Structural basis of immunosuppression by the therapeutic antibody daclizumab

Cell Research

Volumn 20, Issue 12, 2010, Pages 1361-1371

  Yang, Hui ^a,b   Wang, Jianchuan ^a,b   Du, Jiamu ^a,d   Zhong, Chen ^a   Zhang, Dapeng ^c   Guo, Huaizu ^c   Guo, Yajun ^c   Ding, Jianping ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

crystal structure; daclizumab; IL 2 signaling; IL 2R ; therapeutic antibody

Indexed keywords

BASILIXIMAB; DACLIZUMAB; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ARTICLE; BINDING SITE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; GRAFT REJECTION; HUMAN; HYDROGEN BOND; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

ANTIBODIES, MONOCLONAL; BINDING SITES; COMPLEMENTARITY DETERMINING REGIONS; CRYSTALLOGRAPHY, X-RAY; GRAFT REJECTION; HUMANS; HYDROGEN BONDING; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 78649831537     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.130     Document Type: Article

References (62)

1. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240:1169-1176.
2. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998; 70:1-81.
3. Klebb G, Autenrieth IB, Haber H, et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol 1996; 81:282-286.
4. Robb RJ, Munck A, Smith KA. T cell growth factor receptors. Quantitation, specifcity, and biological relevance. J Exp Med 1981; 154:1455-1474.
5. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science 2005; 308:1477-1480.
6. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA 2006; 103:2788-2793.
7. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005; 310:1159-1163.
8. Forsten KE, Lauffenburger DA. The role of low-affinity interleukin-2 receptors in autocrine ligand binding: alternative mechanisms for enhanced binding effect. Mol Immunol 1994; 31:739-751.
9. Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. J Mol Biol 2004; 339:1115-1128.
10. Bazan JF. Structural design and molecular evolution of a cy-tokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87:6934-6938.
11. Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest 1985; 76:446-453.
12. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ. Novel interleukin-2 receptor subunit detected by cross-linking under high-affnity conditions. Science 1986; 234:859-863.
13. Teshigawara K, Wang HM, Kato K, Smith KA. Interleukin 2 high-affnity receptor expression requires two distinct binding proteins. J Exp Med 1987; 165:223-238.
14. Tsudo M, Kozak RW, Goldman CK, Waldmann TA. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 1986; 83:9694-9698.
15. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002; 277:29355-29358.
16. Takeshita T, Asao H, Ohtani K, et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992; 257:379-382.
17. He YW, Malek TR. The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol 1998; 18:503-524.
18. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990; 113:619-627.
19. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007; 26:3699-3703.
20. Waldmann TA. The multi-subunit interleukin-2 receptor. Annu Rev Biochem 1989; 58:875-911.
21. Waldmann TA. The meandering 45-year odyssey of a clinical immunologist. Annu Rev Immunol 2003; 21:1-27.
22. Waldmann TA. The structure, function, and expression of in-terleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232:727-732.
23. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86:10029-10033.
24. Ciancio G, Mattiazzi A, Roth D, Kupin W, Miller J, Burke GW. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin Transplant 2003; 17:428-432.
25. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67:110-115.
26. Pescovitz MD, Bumgardner G, Gaston RS, et al. Pharma-cokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant 2003; 17:511-517.
27. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161-165.
28. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc 1998; 30:2155-2158.
29. Eckhoff DE, McGuire B, Sellers M, et al. The safety and ef-fcacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69:1867-1872.
30. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001; 7:220-225.
31. Innocenti F, Humeres R, Zamboni M, et al. IL-2 receptor blockers in liver transplantation: initial experience with dacli-zumab in Chile. Transplant Proc 2003; 35:2520-2521.
32. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharma-cokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002; 73:1640-1646.
33. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;
34. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95:83-89.
35. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56:864-867.
36. Pascual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant 2001; 16:1756-1760.
37. Kandus A, Arnol M, Omahen K, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation 2010; 89:1022-1027.
38. Du J, Yang H, Zhang D, et al. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J Immunol 2010; 184:1361-1368.
39. Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 2005; 36:69-83.
40. Binder M, Vogtle FN, Michelfelder S, et al. Identifcation of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 2007; 67:3518-3523.
41. Sheriff S, Jeffrey PD, Bajorath J. Comparison of CH1 domains in different classes of murine antibodies. J Mol Biol 1996; 263:385-389.
42. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927-948.
43. Gaboriaud C, Juanhuix J, Gruez A, et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 2003; 278:46974-46982.
44. Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci USA 1996; 93:7-12.
45. Wilson IA, Stanfeld RL. Antibody-antigen interactions. Curr Opin Struct Biol 1993; 234:946-950.
46. Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces. J Mol Biol 1993; 234:946-950.
47. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108:1975-1978.
48. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007; 282:15073-15080.
49. Riemer AB, Klinger M, Wagner S, et al. Generation of pep-tide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004; 173:394-401.
50. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Her-ceptin Fab. Nature 2003; 421:756-760.
51. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol 2005; 139:2-10.
52. Li B, Zhao L, Guo H, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009; 114:5007-5015.
53. Reichert JM. Monoclonal antibodies in the clinic. Nat Bio-technol 2001; 19:819-822.
54. Pfugrath JW. The fner things in X-ray diffraction data collection. Acta Crystallogr 1999; D55:1718-1725.
55. Otwinowski ZMW. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997; 276:307-326.
56. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystal-logr 2005; D61:458-464.
57. Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009; 46:2419-2423.
58. Murshudov GN, Vagin AA, Dodson EJ. Refnement of mac-romolecular structures by the maximum-likelihood method. Acta Crystallogr 1997; D53:240-255.
59. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr 2004; D60:2126-2132.
60. Laskowski RA, Macarthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993; 26:283-291.
61. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr 1994; D50:760-763.
62. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372:774-797.